{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:29:40Z","timestamp":1793449780743,"version":"4.5.0"},"reference-count":21,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"unspecified","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Research Council"},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["CRC1483"],"award-info":[{"award-number":["CRC1483"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,11,30]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Janus kinase inhibitors (JAKi), like baricitinib, are used as monotherapy (MONO) and in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients. This study aimed to evaluate the long-term efficacy, drug survival and safety of baricitinib MONO versus combination therapy (COMBO) in a prospective cohort of patients with RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed data from 219 RA patients initiating baricitinib in a single-centre, prospective observational cohort between 2017 and 2023. Clinical data, patient-reported outcomes and safety events were collected every 3\u2009months. Drug survival was analysed using the Kaplan-Meier method, and longitudinal outcomes were assessed using linear mixed-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 219 patients (165 MONO, 54 COMBO) with high baseline disease activity (mean DAS28-ESR 4.0). Both groups showed rapid and sustained clinical improvement, with disease activity stabilising in the low range by 6\u2009months of treatment. One third of the patients (n=72, 33%) achieved Boolean remission, with no significant difference between groups (p=0.35). Median drug survival was 36 months and was similar for both regimens (log-rank p=0.82). Discontinuation due to adverse events occurred in 10.9% of patients. Four thrombotic events were noted, all in patients with pre-existing cardiovascular risk factors, with no new safety signals emerging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world cohort, baricitinib demonstrated sustained long-term effectiveness, drug survival and an acceptable safety profile. The similar outcomes observed for MONO and COMBO indicate that baricitinib may be used effectively as MONO in patients with RA for whom MTX is not suitable or tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006333","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:35:17Z","timestamp":1765967717000},"page":"e006333","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a real-world prospective cohort study"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0804-3198","authenticated-orcid":false,"given":"Alp","family":"Temiz","sequence":"first","affiliation":[{"name":"Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8109-826X","authenticated-orcid":false,"given":"Koray","family":"Tascilar","sequence":"additional","affiliation":[{"name":"Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel J","family":"Hueber","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Klinikum N\u00fcrnberg, Paracelsus Medical University, N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2799-184X","authenticated-orcid":false,"given":"Sara","family":"Bayat","sequence":"additional","affiliation":[{"name":"Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2025121702350947000_11.4.e006333.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965"},{"key":"2025121702350947000_11.4.e006333.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2025121702350947000_11.4.e006333.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223762"},{"key":"2025121702350947000_11.4.e006333.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223636"},{"key":"2025121702350947000_11.4.e006333.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2025121702350947000_11.4.e006333.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222586"},{"key":"2025121702350947000_11.4.e006333.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"2025121702350947000_11.4.e006333.8","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/art.42617","article-title":"Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial","volume":"75","author":"Simon","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025121702350947000_11.4.e006333.9","first-page":"73","article-title":"The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis","volume":"10","author":"Alten","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025121702350947000_11.4.e006333.10","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004291","article-title":"PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs","volume":"10","author":"van de Laar","year":"2024","journal-title":"RMD Open"},{"key":"2025121702350947000_11.4.e006333.11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s40744-023-00597-3","article-title":"Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients","volume":"10","author":"Alten","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025121702350947000_11.4.e006333.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2025121702350947000_11.4.e006333.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"2025121702350947000_11.4.e006333.14","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/rheumatology\/keae012","article-title":"Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study","volume":"63","author":"Caporali","year":"2024","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025121702350947000_11.4.e006333.15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025121702350947000_11.4.e006333.16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002674","article-title":"Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study","volume":"8","author":"Bayat","year":"2022","journal-title":"RMD Open"},{"key":"2025121702350947000_11.4.e006333.17","doi-asserted-by":"crossref","first-page":"977265","DOI":"10.3389\/fimmu.2022.977265","article-title":"Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"2025121702350947000_11.4.e006333.18","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1080\/03007995.2024.2416979","article-title":"Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world data","volume":"40","author":"Edwards","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"2025121702350947000_11.4.e006333.19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40744-021-00423-8","article-title":"Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)","volume":"9","author":"Hern\u00e1ndez-Cruz","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025121702350947000_11.4.e006333.20","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1093\/rheumatology\/kead074","article-title":"Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data","volume":"62","author":"Edwards","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025121702350947000_11.4.e006333.21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/annrheumdis-2022-eular.3770","article-title":"POS0435\u2005IMPACT OF COMBINATION THERAPY WITH csDMARDs ON THE EFFECTIVENESS OF BIOLOGIC OR TARGETED SYNTHETIC DMARDs IN A REAL-LIFE SETTING: RESULTS FROM THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)","volume":"81","author":"Gilbert","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:35:23Z","timestamp":1765967723000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-006333"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006333","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}